The Zacks: CRISPR THERAPTC (CRSP) Given Average Rating of “Strong Buy” by Analysts – DailyQuint
|
The Zacks: CRISPR THERAPTC (CRSP) Given Average Rating of “Strong Buy” by Analysts
DailyQuint Shares of CRISPR THERAPTC (NASDAQ:CRSP) have been given a consensus broker rating score of 1.00 (Strong Buy) from the two analysts that provide coverage for the company, Zacks Investment Research reports. Two investment analysts have rated the … |
